292 reports of this reaction
1.2% of all ROMIPLOSTIM reports
#18 most reported adverse reaction
DEEP VEIN THROMBOSIS is the #18 most commonly reported adverse reaction for ROMIPLOSTIM, manufactured by Amgen, Inc. There are 292 FDA adverse event reports linking ROMIPLOSTIM to DEEP VEIN THROMBOSIS. This represents approximately 1.2% of all 24,148 adverse event reports for this drug.
Patients taking ROMIPLOSTIM who experience deep vein thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEEP VEIN THROMBOSIS is a less commonly reported adverse event for ROMIPLOSTIM, but still significant enough to appear in the safety profile.
In addition to deep vein thrombosis, the following adverse reactions have been reported for ROMIPLOSTIM:
The following drugs have also been linked to deep vein thrombosis in FDA adverse event reports:
DEEP VEIN THROMBOSIS has been reported as an adverse event in 292 FDA reports for ROMIPLOSTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEEP VEIN THROMBOSIS accounts for approximately 1.2% of all adverse event reports for ROMIPLOSTIM, making it a notable side effect.
If you experience deep vein thrombosis while taking ROMIPLOSTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.